



US006171841B1

(12) **United States Patent**
Akira et al.

(10) **Patent No.:** **US 6,171,841 B1**
(45) **Date of Patent:** **Jan. 9, 2001**

- (54) **DNA CODING FOR SERINE/THREONINE KINASE**
- (75) Inventors: **Shizuo Akira**, Osaka; **Taro Kawai**, Hyogo, both of (JP)
- (73) Assignee: **Japan Science and Technology Corporation**, Kawaguchi (JP)
- (*) Notice: Under 35 U.S.C. 154(b), the term of this patent shall be extended for 0 days.
- (21) Appl. No.: **09/186,277**
- (22) Filed: **Nov. 5, 1998**

Related U.S. Application Data

- (62) Division of application No. 09/159,385, filed on Sep. 23, 1998, now Pat. No. 5,958,748.

(30) **Foreign Application Priority Data**

Sep. 26, 1997 (JP) 9-261589

- (51) **Int. Cl.**⁷ **C12N 9/12**; C07H 21/04
- (52) **U.S. Cl.** **435/194**; 435/252.33; 435/254.11; 435/320.1; 536/23.1; 536/23.2; 536/23.5
- (58) **Field of Search** 435/194, 252.33, 435/254.11, 320.1; 536/23.1, 23.2, 23.5

(56) **References Cited**

PUBLICATIONS

Chien et al.; "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest"; Proceedings of the National Academy of Sciences

of USA; vol. 88; Nov. 1, 1991; pp. 9578-9582; XP000647704.

Holzman et al.; "Identification, .molecular cloning, and characterization of dual leucine zipper bearing kinase"; vol. 269, No. 49; 1994; pp. 30808-30817; XP002120730.

Kawai et al.; "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis"; Molecular and Cellular Biology; vol. 18, No. 3; Mar. 1998; pp. 1642-1651; XP002120731.

Hillier et al.; "*Homo sapiens* cDNA clone similar to DAP kinase"; EMBL Database Entry HS936258; Accession No. N23936; Dec. 30, 1995; Abstract; XP002120726.

Strausberg; "*Homo sapiens* cDNA clone similar to DAP kinase"; EMBL Database Entry AA557328; Accession No. AA557328; Sep. 11, 1997; Abstract; XP002120727.

Marra et al.; "*Mus musculus* cDNA clone similar to DAP kinase"; EMBL Database Entry MMAA13041; Accession No. AA22667; Feb. 3, 1997; Abstract; XP002120729.

Primary Examiner—Nashaat Nashed
(74) *Attorney, Agent, or Firm*—Foley & Lardner

(57) **ABSTRACT**

The nucleic acid sequence encoding mammalian serine/threonine protein kinase comprising a leucine zipper motif (Zip-kinase) and the corresponding amino acid sequence are disclosed. The Zip-kinase is a nuclear enzyme having activity of inducing apoptosis. A victor and a transformed cell with the nucleic acid sequence as well as recombinant method of making the Zip-kinase utilizing the transformed cell are taught.

10 Claims, 10 Drawing Sheets

(2 of 10 Drawing Sheet(s) Filed in Color)

FIG. 1

	Protein kinase domain		
mouse ZIP-kinase	MSTFRQEDVEDHYEMGEELGSGQFAIVRKCCQKGTGMEYAAKFIKKRRLPSSRRGVSREE	60	
human ZIP-kinase	MSTFRQEDVEDHYEMGEELGSGQFAIVRKCRQKGTGKEYAAKFIKKRRLSSRRGVSREE	60	
mouse ZIP-kinase	IEREVSILREIRHPNIITLHDVFNKTDVVLILELVSGGELFDFLAEKESL TEDEATQFL	120	
human ZIP-kinase	IEREVNIIREIRHPNIITLHDIFENKTDVVLILELVSGGELFDFLAEKESL TEDEATQFL	120	
mouse ZIP-kinase	KQILDGVHYLHMKRIAHFDLKPENIMLLDKHAA SPRIKLIDFGIAHRIEAGSEFKNIFGT	180	
human ZIP-kinase	KQILDGVHYLHMKRIAHFDLKPENIMLLDKNVPNRIKIDFGIAHKIEAGNEFKNIFGT	180	
mouse ZIP-kinase	PEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEY	240	
human ZIP-kinase	PEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEY	240	
mouse ZIP-kinase	FSSTSELAKDFIRLLLVKDPKRRMTIAQSLEHSWIK-VRRR-----EDGARKPERRRLRAA	295	
human ZIP-kinase	FSNTSELAKDFIRLLLVKDPKRRMTIAQSLEHSWIKAIRRNVRGSDSGRKPERRRLKTT	300	
mouse ZIP-kinase	RLREYSLKSHSMPNNTSYASFERFSRVLEDVAAAEEQGLRELQGRRQCRERVCA RAA	355	
human ZIP-kinase	RLKEYTIKSHSSLPPNNSYADFERFSKVL EAAAAAEEGLRELQRSRLCHEDVEALAAIY	360	
mouse ZIP-kinase	EQREARCRDGSAGLGRDLRRLRTELGRTEALRTAQEEARAALLGAGGLKRRLCRL ENRY	415	
human ZIP-kinase	EEKEAWYREESDSLGDQLRRLRQELKTEALKRQAQEEAKGALLGTSGLKRRFSRLENRY	420	
mouse ZIP-kinase	DALAAQVAAEVQFVRDLVRALEQERLQA-ECGVR	448	
human ZIP-kinase	EALAKQVA SEMRFVQDLVRALEQEKLQGVCEGLR	454	
	Leucine zipper domain		

FIG. 2




FIG. 3




FIG. 4




FIG. 6






FIG. 7


Mock



ZIP-kinase



ZIP-kinase K42A



ZIP-kinase LA




FIG. 8




FIG. 9A





FIG. 9B

FIG. 10A

FLAG-ATF4



FLAG-ZIP-kinase K42A




FIG. 10B

DNA CODING FOR SERINE/THREONINE KINASE

This is a divisional application based on U.S. application Ser. No. 09/159,385, filed Sep. 23, 1998, now U.S. Pat. No. 5,958,748, the contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a serine/threonine kinase, a DNA coding for said kinase, a recombinant vector comprising said DNA, a transformant transformed with said vector, and a process for preparing the serine/threonine kinase.

2. Prior Art

Various signals from the exterior of a cell are transmitted through receptors on the cell surface into the cell and ultimately into the nucleus. The signals transmitted into the nucleus activate transcription factors and, as a result, expression of a group of genes is induced or repressed to produce phenotypes such as cell proliferation, differentiation and cell death. Many transcription factors have been cloned and the structure of functional domains have been elucidated: MOLECULAR BIOLOGY OF THE CELL THIRD EDITION, pp. 401-469. These functional domains are known to include leucine zipper, helix-loop-helix and zinc finger structures. Among them, the leucine zipper structure is a motif commonly found in such transcription factors as Jun/Fos, ATF/CREB and C/EBP families and these transcription factors form homo- or hetero-dimers through their leucine zipper structures to control the transcription of specific genes: Hai, T. et al., Proc. Natl. Acad. Sci., USA, 88:3720-3724 (1991).

Recently, it is reported that the leucine zipper structure is also found other functional molecules than the transcription factors (Holzman, L. B. et al., J. Biol. Chem., 269:30808-30817, 1994), suggesting that the leucine zipper structure not only facilitates the binding between transcription factors but also acts generally as a protein-protein interactional domain in cells.

Therefore, identification of molecules interacting with the leucine zipper domain is considered to be useful in analyzing not only new functions of transcription factors but also functions of the leucine zipper structure in other molecules than the transcription factors.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a serine/threonine kinase, a DNA coding for said kinase, a recombinant vector comprising said DNA, a transformant transformed with said vector, and a process for preparing the serine/threonine kinase.

As a result of their eager studies based on the above described problems, the present inventors have succeeded in isolating a DNA coding for a serine/threonine kinase from cDNA libraries prepared from human placenta and mouse brain and thus completed the present invention.

Accordingly, the present invention is the following recombinant protein (a) or (b):

- (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 1;
- (b) a protein comprising an amino acid sequence having one or several amino acids deleted, substituted or added in the amino acid sequence as shown in SEQ ID NO: 1, and exhibiting a serine/threonine kinase activity.

Also, the present invention is the following recombinant protein (c) or (d):

- (c) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2;
- (d) a protein comprising an amino acid sequence having one or several amino acids deleted, substituted or added in the amino acid sequence as shown in SEQ ID NO: 2, and exhibiting a serine/threonine kinase activity.

Further, the present invention is a DNA coding for said protein. The DNA include, for example, those comprising the base sequence as shown in SEQ ID NO: 3 or 4.

The present invention is also a recombinant vector comprising said DNA.

Still further, the present invention is a transformant transformed with the recombinant vector.

Finally, the present invention is a process for producing a serine/threonine kinase comprising cultivating the transformant in a culture medium and collecting the serine/threonine kinase from the resulting culture.

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawings will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

The present invention will hereinbelow be described in detail with reference to the drawings attached in which:

FIG. 1 shows the results of homology search in amino acid sequence between human ZIP-kinase (SEQ ID NO: 1) and mouse ZIP-kinase (SEQ ID NO: 2);

FIG. 2 shows the results of homology search in amino acid sequence between human ZIP-kinase (SEQ ID NO: 1), mouse ZIP-kinase (SEQ ID NO: 2), human DAP-kinase and mouse DAP-kinase;

FIG. 3 is an electrophoretic photograph showing the results of western blot;

FIG. 4 is a photograph (the form of an organism) showing the results of colony formation in a selective medium;

FIG. 5 is an electrophoretic photograph showing the results of northern blot;

FIG. 6 is a photograph (the form of an organism) showing the results of colony formation in a selective medium;

FIG. 7 is a photograph of NIH3T3 (the form of an organism) showing the form of apoptosis;

FIG. 8 shows the fraction of LacZ expression cells showing the form of apoptosis;

FIGS. 9A and 9B are electrophoretic photographs showing the kinase activity of ZIP-kinase; and

FIGS. 10A and 10B are photographs (the form of an organism) showing the intracellular localization of ZIP-kinase.

DESCRIPTION OF THE INVENTION

The recombinant protein according to the present invention, hereinafter also referred to as "ZIP-kinase", is a protein molecule binding to the leucine zipper domain of a transcription factor called ATF4, and has a serine/threonine kinase activity. The ZIP-kinase is a novel nuclear serine/threonine kinase having the leucine zipper structure and has an activity to induce apoptosis. ATF4 is a leucine zipper type transcription factor which binds to cAMP response element (CRE) and belongs to the ATF/CREB family.

On the other hand, the DNA according to the present invention is obtained from cDNA libraries prepared from

human placenta and mouse brain by screening them using so-called yeast two-hybrid system, and codes for ZIP-kinase. Hereinafter, the DNA will also be referred to as "ZIP-kinase DNA".

The DNA according to the present invention may be cloned in the following manner:

1. Cloning of ZIP-kinase DNA

(1) Preparation of cDNA Libraries from Human Placenta and Mouse Brain

Sources of mRNA may include tissues such as human placenta and mouse brain. Established cell lines from these tissues may also be used as the source.

The mRNA may be prepared by conventional procedures. For instance, total RNA may be obtained by treating the tissue or cell with a guanidine reagent, and poly (A+) RNA (mRNA) may be obtained by an affinity column method using oligo dT-cellulose or poly U-Sepharose on Sepharose 2B as a carrier, or by a batch method. Also, the poly (A+) RNA may further be fractionated by sucrose density-gradient centrifugation.

The resulting mRNA is used as a template to synthesize a single-stranded cDNA which is in turn used to synthesize a double-stranded cDNA. A recombinant plasmid is prepared from a suitable vector DNA and used to transform *Escherichia coli* or the like to yield a cDNA library.

Alternatively, the cDNA library may be commercially available (CLONETECH).

(2) Construction of Plasmid pAS2-1

From the cDNA library obtained in (1) above, a plasmid is prepared for screening for a desired clone.

Such a plasmid may be obtained by preparing a chimeric DNA by ligating a DNA coding for mouse ATF4 leucine zipper domain (amino acids 298 to 349 in the sequence of ATF4) to a DNA coding for GAL4 DNA binding domain, and ligating the chimeric DNA to bait plasmid pAS2-1.

(3) Screening

Then said plasmid is used to screen the cDNA library. In the screening, yeast two-hybrid system may be used. The yeast two-hybrid system is an experimental system capable of detecting interaction between proteins in yeast and is capable of screening the library for cDNA of a protein interacting with the desired protein (bait).

Positive clones may be selected using the growth in a selective medium free of histidine, tryptophan or leucine and the activity of β -galactosidase.

(4) Determination of Base Sequence

The base sequence is determined for the resulting clone. The sequencing may be carried out by any known method such as Maxam-Gilbert method or the dideoxy method and is usually done using an automated base sequencer.

SEQ ID NOs: 1 and 2 exemplify the amino acid sequence of ZIP-kinase and the base sequence of ZIP-kinase DNA, respectively, according to the present invention. As far as a protein comprising said amino acid sequence has an activity as a serine/threonine kinase, there may be a mutation or variation of deletion, substitution and/or addition of one or several amino acids in said amino acid sequence as shown in SEQ ID NO: 1. For example, a protein having the amino acid sequence as shown in SEQ ID NO: 1 from which the first amino acid methionine has been deleted may also be included in the present invention.

Herein the serine/threonine kinase activity means an activity of transferring the terminal phosphate group of ATP to a certain amino acid (serine or threonine) of a protein. The introduction of mutation or variation may be carried out by any known method (Deng, W. P. et al., *Anal. Biochem.*, 200: 81, 1992) or using a commercially available kit (Site-Directed Mutagenesis Kit of CLONETECH).

Once the base sequence of ZIP-kinase DNA according to the present invention is determined, ZIP-kinase DNA according to the present invention may then be obtained by chemical synthesis, or by PCR with various tissues-derived cDNA as a template, or hybridization of a DNA fragment having said base sequence as a probe.

2. Construction of Recombinant Vector and Transformant

(1) Construction of Recombinant Vector

The recombinant vector of the present invention may be obtained by ligating or inserting ZIP-kinase DNA of the present invention into an appropriate vector. The vector for inserting ZIP-kinase DNA of the present invention is not particularly limited as long as it can be replicated in a host, and may include plasmid DNA, phage DNA, etc. The plasmid DNA may be prepared from *E. coli* or *Agrobacterium* by the alkali extraction (Birnboim, H. C. & Doly, J., (1979) *Nucleic acid Res.*, 7:1513) or modified method. Further, commercially available plasmids may also be used, for example, pUC18 (Takara Shuzo), pUC19 (Takara Shuzo), pBluescript SK+ (stratagene), pGEM-T (Promega), pT7Blue (Novagen) and PBR322 (Takara Shuzo).

The phage DNA may include, for example, M13mp18, M13mp19, λ gt10, λ gt11, etc.

When the DNA of the present invention is inserted into a vector, the purified DNA may first be cut with a suitable restriction enzyme and inserted into a restriction enzyme site or multi cloning site of a suitable vector DNA to ligate with the vector.

The DNA of the present invention should be incorporated into a vector such that the function of the DNA can be realized. In addition to a promoter and the DNA of the present invention, the vector of the present invention may comprise a terminator, a ribosome-binding sequence and the like. The terminator may be a stop codon such as TGA, TAG or TAA and the ribosome-binding sequence may be a leader sequence.

(3) Preparation of Transformant

The transformant of the present invention may be obtained by introducing the recombinant expression vector of the present invention into a host such that the desired gene can be expressed therein.

The host is not particularly limited so long as the DNA of the present invention can be expressed and may include, for example, bacteria belonging to the genus *Escherichia* or *Bacillus*, such as *Escherichia coli* and *Bacillus subtilis*; yeast, such as *Saccharomyces cerevisiae* and *Saccharomyces pombe*; animal cells, such as COS and CHO cells; and insect cells, such as Sf9.

When a bacterium, such as *E. coli*, is used as a host, it is preferred that the vector of the present invention is capable of autonomously replicating in said bacterium and comprises a promoter, a ribosome-binding sequence, the DNA of the present invention, and a transcription terminating sequence. The vector may also comprise a gene controlling the promoter.

For example, pET and pGEX (Pharmacia) may be used as the expression vector.

Any promoter may be used so long as the expression can be effected in the host such as *E. coli*. A promoter derived from *E. coli* or phage, such as trp, lac, PL or PR promoter, may be used. An artificially designed and modified promoter, such as T7 or T3, may also be used.

The method for introducing the recombinant vector into a bacterium is not particularly limited so long as a DNA can be introduced into a bacterium. For example, the method using calcium ion (Proc. Natl. Acad. Sci., USA, 69, 2110-2114 (1972)) and the electroporation method may be used.

When a yeast is used as a host, YEp13, YEp24 and YCp50 may be used as the expression vector. The promoter used is not particularly limited so long as the expression in the yeast can be effected, and may include, for example, gal1, gal10, heat shock protein, MF α 1 and SV40 promoters.

The method for introducing the recombinant vector into a yeast is not particularly limited so long as a DNA can be introduced into a yeast, and include, for example, the electroporation method (Methods Enzymol., 194, 182-187 (1990)), the spheroplast method (Proc. Natl. Acad. Sci., USA, 84, 1929-1933 (1978)), and the lithium acetate method (J. Bacteriol., 153, 163-168 (1983)).

When an animal cell is used as a host, an expression vector, such as pcDNAI/Amp or pcDNAI (Invitrogen) is used. The promoter used may also be the early gene promoter of human cytomegalovirus.

The method for introducing the recombinant vector into an animal cell may include, for example, the electroporation method, the calcium phosphate method and the lipofection method.

The recombinant vectors of the present invention (one vector containing ZIP-kinase DNA from human placenta and another vector containing ZIP-kinase DNA from mouse brain) have been introduced into *E. coli* DH5, *E. coli* (hZIP-kinase) DH5 and *E. coli* (mZIP-kinase) DH5, respectively, and deposited at National Institute of Bioscience and Human-Technology (NIBH), Agency of Industrial Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 305, Japan on Sep. 25, 1997 under Accession Nos. FERM BP-6487 and FERM BP-6488, respectively.

3. Production of ZIP-kinase

ZIP-kinase of the present invention may be obtained by cultivating the transformant in a culture medium and collecting from the resulting culture.

The transformant of the present invention may be cultivated in a culture medium by any method conventionally used to cultivate a host.

The culture medium for cultivating a transformant obtained from a microorganism such as *E. coli* or yeast as a host may be either a natural or synthetic medium so long as it contains a carbon source, a nitrogen source and inorganic salts which can be utilized by the microorganism and the transformant can efficiently be cultivated.

The carbon source used may include carbohydrates, such as glucose, fructose, sucrose, starch, and dextrose; organic acids, such as acetic acid and propionic acid; and alcohols, such as ethanol and propanol.

The nitrogen source which may be used includes ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium sulfate, ammonium acetate and ammonium phosphate; other nitrogen containing compounds; peptone, meat extract, corn steep liquor, and yeast extract.

The minerals which may be used include monobasic potassium phosphate, dibasic potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, calcium chloride, and disodium phosphate.

The cultivation is generally carried out at 37° C. for 12 to 18 hours under aerobic conditions, such as shaking culture

and aerated spinner culture. During the cultivation, pH is kept at 7.0 to 7.5. The pH is adjusted with an inorganic or organic acid or alkaline solution, or carbonic acid gas.

During the cultivation, an antibiotic such as ampicillin or tetracycline may optionally be added to the medium.

When a microorganism transformed with an expression vector comprising an inducible promoter is cultivated, an inducer may be added to the medium, if necessary. For example, when a microorganism transformed with an expression vector comprising Lac promoter is cultivated, isopropyl- β -D-thiogalactopyranoside (IPTG) or the like may be added to the medium. When a microorganism transformed with an expression vector comprising trp promoter is cultivated, indole-acrylic acid (IAA) may be added to the medium.

When a transformant obtained from an animal cell as a host is cultivated, a conventional culture medium such as RPMI 1640 or DMEM medium or these media to which fetal bovine serum is added may be used.

The cultivation is generally carried out at 37° C. for 1 to 3 days in the presence of 5% CO₂.

During the cultivation, an antibiotic such as kanamycin or penicillin may be added to the medium.

After the cultivation, when ZIP-kinase of the present invention is produced in the host cell, the ZIP-kinase is extracted by disruption of the cell. When ZIP-kinase of the present invention is produced in the exterior of the cell, the culture may be directly used as it is, or the ZIP-kinase of the present invention may be isolated and purified from the culture, after removing the cell by centrifugation, using any conventional biochemical methods generally used in the isolation and purification of proteins, such as ammonium sulfate precipitation, gel chromatography, ion exchange chromatography and affinity chromatography, singly or in any combination thereof.

EXAMPLES

The present invention will be further illustrated by the following examples. However, the scope of the present invention is not limited to these examples.

Example 1

Cloning of ZIP-kinase DNA

(1) Preparation of cDNA Library

A commercially available cDNA (CLONETECH) was used in the present invention.

(2) Construction of Plasmid

DNA coding for leucine zipper domain of mouse ATF4 was obtained by PCR method.

The composition of the PCR reaction was 1.0 μ g DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM dNTP, 0.5 μ M primer, and 1 U Taq.

The following primers were used:

Sense primer: 5'-GGGAATTCGGAGCAGGAGGCT-3' (SEQ ID NO: 5)

Antisense primer: 5'-GGGGATCCCTAGGGACCCCTTTTCTA-3' (SEQ ID NO: 6)

60

PCR reaction was first carried out at 94° C. for 1 minute. Then, 25 cycles of reactions at 94° C. for 20 seconds, at 56° C. for 20 seconds and at 72° C. for 30 seconds were carried out. Finally, the reaction at 72° C. for 10 minutes was effected.

The PCR products were cut with EcoRI/BamHI and inserted into EcoRI/BamHI site of pAS2-1 vector. The

plasmids were used to transform *E. coli* DH5 α and purified by means of a commercially available kit (Wizard miniprep: Promega) based on alkali-SDS method. This plasmid capable of expressing a fused protein of GAL4 DNA binding domain in yeast was used as a bait.

(3) Screening

Yeast strain Y190 was transformed with the plasmid as a bait using MATCHMAKER Two-Hybrid System kit of CLONETECH. Transformants were selected by growth in tryptophan(-) medium as an index. Further, cDNA libraries capable of expressing a fusion protein with GAL4 transcription activating domain (CLONETECH, mouse brain and human placenta MATCHMAKER cDNA libraries) were

Sense primer: 5' -GGGTCGACCAC CATGGCTTAC CCATACGATG TTCCAGATTA CGCTATGTC ACATTCAGGC AA-3'

Antisense primer: 5' -GGGTCGACTA GCGCACGCCG CACTCAGCCT GC-3'

transformed. Transformants can grow in tryptophan(-), leucine(-) medium. Further, since reporter genes, HIS3 and LacZ genes, were transcribed if the bait bound to the DNA coding for the protein from the library, positive clones can grow in tryptophan(-), leucine(-), histidine(-) medium and provides blue color in the presence of X-gal because of their β -galactosidase activity. Plasmids were purified from the positive clones using MATCHMAKER Two-Hybrid System kit of CLONETECH, and used to transform *E. Coli*. Plasmids were purified from the resulting transformants and the base sequences thereof were determined (ABI model 377). The resulting base sequences were searched for homology using GenBank, EMBL, DDBJ data base.

As a result, those having high homology (20% or higher) with the previously reported C/EBP family, AP-1 family and genes having leucine zipper structure were identified as novel genes. Seven (7) and 2 clones of such genes were obtained from mouse brain and human placenta cDNA libraries, respectively. All these genes were derived from an identical gene.

(4) Determination of Base Sequence

The thus obtained gene was considered to code for a kinase and the DNA coding for this novel kinase was designated as ZIP-kinase DNA (Zipper Interacting Protein Kinase DNA). The base sequence of the full length ZIP-kinase DNA was determined.

The base sequences of ZIP-kinase DNA obtained from human placenta and mouse brain are shown in SEQ ID NOs: 3 and 4, respectively. The amino acid sequences encoded by the base sequences of SEQ ID NOs: 3 and 4 are shown in SEQ ID NOs: 1 and 2, respectively.

The amino acid sequence encoded by ZIP-kinase DNA obtained from human placenta (human ZIP-kinase) and the amino acid sequence encoded by ZIP-kinase DNA obtained from mouse brain (mouse ZIP-kinase) were searched for homology therebetween and the leucine zipper domain and serine/threonine kinase domain were found in the C- and N-terminal of the respective amino acid sequences, respectively (FIG. 1). Further, mouse and human ZIP-kinases consisted of 448 and 454 amino acids, respectively, and the homology between mouse and human was 84.9% at amino acid level.

Moreover, the kinase domains of the ZIP-kinases showed high homology with DAP-kinases positively controlling apoptosis caused by IFN- γ , suggesting that these kinases form a new family (FIG. 2).

Example 2

Construction of Recombinant Vector and Preparation of Transformant

To construct a recombinant vector of ZIP-kinase DNA, cDNA coding for ZIP-kinase was synthesized by PCR method.

The PCR reaction mixture and primers used were as follows.

The composition of the PCR reaction was 1.0 μ g DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM dNTP, 0.5 μ M primer, and 1 U Taq.

(SEQ ID NO: 7)

(SEQ ID NO: 8)

PCR reaction was first carried out at 96° C. for 1 minute. Then, 30 cycles of reactions at 96° C. for 30 seconds, at 56° C. for 30 seconds and at 72° C. for 1 minute were carried out. Finally, the reaction at 72° C. for 10 minutes was effected.

The resulting PCR products were cut with SalI, inserted into expression vector pEF-BOS (Takara, Ligation kit), and used to transform *E. Coli* DH5 (TOYOBO). Plasmids were purified from the *E. Coli* (Promega, Wizard miniprep) and confirmed by DNA sequence (ABI, model 377).

A DNA coding for a variant of ZIP-kinase in which the 42nd amino acid lysine in the amino acid sequence as shown in SEQ ID NO: 2 was changed to alanine, hereinafter referred to as "ZIP-kinase K42A", was constructed by using Site-Directed Mutagenesis Kit of CLONETECH. Also, a DNA coding for another variant in which the 422nd and 429th amino acids valine and the 436th amino acid leucine in the amino acid sequence as shown in SEQ ID NO: 2 were changed to alanines, hereinafter referred to as "ZIP-kinase LA", was similarly constructed.

Example 3

Function of DNA of the Present Invention

(1) Binding of ZIP-kinase to ATF4 in Cells

Whether ZIP-kinase binds to ATF4 in cells as well or not was investigated.

First, DNA coding for mouse ZIP-kinase (309-448 amino acids in the amino acid sequence as shown in SEQ ID NO: 2) was inserted into expression vector pEF-BOS. Thus, a tag of the transcription factor Myc was provided at the N-terminal end of ZIP-kinase, whereby a DNA coding for Myc-ZIP-kinase complex was designated to have the tag as an epitope to construct the vector (pEF-BOS-Myc-ZIP-kinase). Also, an expression vector (pEF-BOS-FLAG-ATF4) was constructed comprising a DNA coding for human ATF4 (full length)-FLAG complex in which FLAG epitope had been added to the N-terminal end of human ATF4.

These vectors were transiently introduced into COS-7 cell line by the lipofection method and expressed (FIG. 3 in which lanes 1, 4, 7 and 10 represent FLAG-ATF4; lanes 2, 5, 8 and 11 Myc-ZIP-kinase; lanes 3, 6, 9 and 12 FLAG-ATF4 and Myc-ZIP-kinase). 36 hours after the introduction, the cells were collected and solubilized with 0.5% Nonidet P-40 lysis buffer. The resulting solubilized cell (WCE: whole cell extract) was developed in SDS-PAGE, and transferred to nitrocellulose membrane. Western blot analysis

was done using anti-FLAG monoclonal antibody (FIG. 3, lanes 1, 2 and 3) and anti-Myc monoclonal antibody (lanes 7, 8 and 9) to confirm the expression of Myc-ZIP-kinase and FLAG-ATF4.

Subsequently, the WCE was immunoprecipitated with anti-Myc monoclonal antibody and the precipitate was subjected to the western blot analysis using anti-FLAG monoclonal antibody, attempting to detect co-immunoprecipitation of Myc-ZIP-kinase and FLAG-ATF4 (FIG. 3, lanes 4 to 6).

As a result, a band of FLAG-ATF4 was detected in lane 6 (FIG. 3). For further confirmation, the WCE was then immunoprecipitated with anti-FLAG monoclonal antibody and the precipitate was subjected to the western blot analysis using anti-Myc monoclonal antibody (lanes 10, 11 and 12). A band of Myc-ZIP-kinase immunoprecipitated with FLAG-ATF4 was found only in lane 12.

Thus, it was shown that ZIP-kinase and ATF4 bind to each other in cells as well.

From this result that ZIP-kinase and ATF4 binds to each other, it may be considered that ATF4 may possibly control the activity of ZIP-kinase.

(2) Determination of Domain Necessary for Binding of ZIP-kinase to ATF4

The site to which ZIP-kinase and ATF4 bind was determined using yeast two-hybrid system. First, variants of mouse ZIP-kinase were prepared: 1) amino acids 278 to 448 of ZIP-kinase (ZIP-kinase 278-448); 2) leucine zipper domain of ZIP-kinase (amino acids 398 to 448) (ZIP-kinase LZ); and 3) a variant of ZIP-kinase in which valine and leucine in the leucine zipper domain were substituted with alanine (ZIP-kinase LA). Each of these variants was designed to produce a chimeric protein with GAL4 trans activating domain, and DNA coding for said chimeric protein was inserted into pACT2 and introduced into yeast strain Y190 together with pAS2-1-ATF4 LZ. The strain was cultivated on histidine+, tryptophan-, leucine-, and histidine-, tryptophan-, leucine- selective media.

Yeast containing DNA coding for ZIP-kinase 278-448 and yeast containing DNA coding for ZIP-kinase LZ could form a colony on the histidine-, tryptophan-, leucine-medium, indicating that ZIP-kinase bound to ATF4 through leucine zipper domain present at the C-terminal (FIG. 4). Further, when valine and leucine in the leucine zipper domain structure were substituted with alanine, the binding to ATF4 was no longer found.

Accordingly, it has been elucidated that ZIP-kinase and ATF4 bind to each other through their respective leucine zipper domain.

(3) Expression of ZIP-kinase in Each Tissue

Northern blot analysis was carried out to investigate the expression of ZIP-kinase in each tissue.

As shown in FIG. 5, mRNA of ZIP-kinase (about 1.4 kb) was distributed almost all tissues investigated. However, only low expression was observed in the spleen.

(4) Confirmation of Formation of Homodimer of ZIP-kinase

The leucine zipper domain present at the C-terminal of ZIP-kinase is considered to be a domain through which proteins bind to each other. Whether ZIP-kinase forms a homodimer or not was investigated. Plasmid pAS2-1 into which DNA coding for leucine zipper domain of ZIP-kinase was inserted, and plasmid pACT2 into which DNA coding for the leucine zipper domain of ZIP-kinase and a variant in which valine and leucine in said domain were substituted with alanine, were co-introduced into yeast and colony formation was observed in a selective medium.

As shown in FIG. 6, only yeast co-expressing the ZIP-kinase leucine zipper domain could grow in histidine-, tryptophan-, leucine- medium. Thus, it has been elucidated that ZIP-kinase forms a homodimer through its leucine zipper structure.

(5) Induction of Apoptosis by ZIP-kinase

It has been shown that DAP-kinase, which has high homology with kinase domain of ZIP-kinase, induces apoptosis in HeLa cell. Whether ZIP-kinase has an apoptosis activity was investigated.

RNA wild type ZIP-kinase tagged with HA (pEF-BOS-HA-ZIP-kinase), a variant thereof in which lysine (42nd amino acid), which is present in ZIP-kinase subdomain II and conserved in other kinases, was substituted with alanine (pEF-BOS-HA-ZIP-kinase K42A), and a variant in which valine and leucine in the leucine zipper domain were substituted with alanine (pEF-BOS-HA-ZIP-kinase LA) were prepared, and DNA coding for each of these proteins was transiently introduced into NIH 3T3 cell together with LacZ expression vector (pEF-BOS-LacZ). After 36 hours from the introduction, X-gal staining was effected.

As a result, a form of cells stained blue was observed under a microscope (FIG. 7). As compared with a control pEF-BOS-mock (FIG. 7, left, upper), the cell into which the wild type ZIP-kinase was introduced (FIG. 7, right, upper) exhibited a typical form of apoptosis associated with agglomeration of nucleus. The fraction of LacZ expression cells showing the apoptosis form was measured to be 44.9% (FIG. 8).

On the other hand, such change of form was not observed in the ZIP-kinase-K42A variant (FIG. 7, left, lower) and there was no significant difference in the fraction of apoptosis between the variant and control. Further, in the ZIP-kinase-LA (FIG. 7, right, lower), some cells caused apoptosis but the fraction thereof was significantly reduced as compared with the wild type.

From the above results, the kinase activity of ZIP-kinase is considered to be essential for the induction of apoptosis by the expression of ZIP-kinase. Further, since apoptosis was suppressed in variants in which a homodimer between ZIP-kinases was inhibited, it is suggested that ZIP-kinases form a homodimer to become an activated form.

(6) Kinase Activity of ZIP-kinase

Whether ZIP-kinase indeed has an activity as a kinase was investigated.

Each of pEF-BOS-HA-ZIP-kinase, pEF-BOS-HA-ZIP-kinase K42A, and pEF-BOS-HA-ZIP-kinase LA was transiently introduced into COS-7 cell, and 36 hours later, the cell was collected and solubilized with 0.5% Nonidet P-40 lysis buffer. The solubilized cell was immunoprecipitated with anti-HA monoclonal antibody and the kinase activity in the precipitate was detected by in vitro kinase assay (FIG. 9A).

As a result, a band of phosphorylation by ZIP-kinase was observed at about 50 kDa in the wild type ZIP-kinase (FIG. 9A, lane of HA-ZIP-kinase), while no band corresponding thereto was observed in ZIP-kinase K42A. On the other hand, a phosphorylation band was observed in ZIP-kinase LA. However, when the expression of HA-ZIP-kinase and its variant in the solubilized cell was checked by the western blotting using anti-HA monoclonal antibody, the amount of HA-ZIP-kinase expressed was markedly reduced as compared with the other two variants (FIG. 9B). From this result, it may be considered that the kinase activity observed in ZIP-kinase LA would be very weak as compared with the wild type.

Further, the amount of wild type ZIP-kinase expressed was low in COS-7 cells; this is considered to be resulted from some lethal effect, such as apoptosis, of ZIP-kinase on COS-7 cells.

(7) Localization of ZIP-kinase in Cells

Knowledge of intracellular localization of ZIP-kinase would be considered to be very effective in analyzing the functions of ZIP-kinase. The present inventors have investigated the localization of ZIP-kinase using a confocal laser microscope.

An expression vector (pEF-BOS-FLAG-ATF4) comprising DNA coding for ATF4 tagged with FLAG or another vector (pEF-BOS-FLAG-ZIP-kinase K42A) coding for ZIP-kinase K42A tagged with FLAG was transiently introduced into COS-7 cells. After 36 hours, the cells were fixed, reacted with anti-FLAG monoclonal antibody, and stained using FITC-labelled anti-mouse immunoglobulin antibody as a secondary antibody.

When observed under the confocal laser microscope, the cytoplasm was not stained and the nucleus was stained in the FLAG-ATF4 introduced cells (FIG. 10A). When the local-

ization of FLAG-ZIP-kinase was similarly investigated, the same staining pattern as in ATF4 was observed, confirming that it was localized in the nucleus (FIG. 10B).

Accordingly, it could be concluded that the ZIP-kinase is a novel nuclear serine/threonine kinase.

Advantages of the Invention

According to the present invention, there are provided a serine/threonine kinase, a DNA coding for said kinase, a recombinant vector comprising said DNA, and a transformant transformed with said vector, and a process for the preparation of the serine/threonine kinase.

Since the ZIP-kinase has a function of inducing apoptosis, the ZIP-kinase and DNA coding for said kinase are useful in being utilizable as a gene therapeutical agent against a cancer and as an anti-cancer agent.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 454

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

Met Ser Thr Phe Arg Gln Glu Asp Val Glu Asp His Tyr Glu Met Gly
 1           5           10           15
Glu Glu Leu Gly Ser Gly Gln Phe Ala Ile Val Arg Lys Cys Arg Gln
 20           25           30
Lys Gly Thr Gly Lys Glu Tyr Ala Ala Lys Phe Ile Lys Lys Arg Arg
 35           40           45
Leu Ser Ser Ser Arg Arg Gly Val Ser Arg Glu Glu Ile Glu Arg Glu
 50           55           60
Val Asn Ile Leu Arg Glu Ile Arg His Pro Asn Ile Ile Thr Leu His
 65           70           75
Asp Ile Phe Glu Asn Lys Thr Asp Val Val Leu Ile Leu Glu Leu Val
 85           90           95
Ser Gly Gly Glu Leu Phe Asp Phe Leu Ala Glu Lys Glu Ser Leu Thr
 100          105          110
Glu Asp Glu Ala Thr Gln Phe Leu Lys Gln Ile Leu Asp Gly Val His
 115          120          125
Tyr Leu His Ser Lys Arg Ile Ala His Phe Asp Leu Lys Pro Glu Asn
 130          135          140
Ile Met Leu Leu Asp Lys Asn Val Pro Asn Pro Arg Ile Lys Leu Ile
 145          150          155
Asp Phe Gly Ile Ala His Lys Ile Glu Ala Gly Asn Glu Phe Lys Asn
 165          170          175
Ile Phe Gly Thr Pro Glu Phe Val Ala Pro Glu Ile Val Asn Tyr Glu
 180          185          190
Pro Leu Gly Leu Glu Ala Asp Met Trp Ser Ile Gly Val Ile Thr Tyr
 195          200          205
Ile Leu Leu Ser Gly Ala Ser Pro Phe Leu Gly Glu Thr Lys Gln Glu
 210          215          220
Thr Leu Thr Asn Ile Ser Ala Val Asn Tyr Asp Phe Asp Glu Glu Tyr
 225          230          235          240

```


-continued

Asp Phe Gly Ile Ala His Arg Ile Glu Ala Gly Ser Glu Phe Lys Asn
 165 170 175

Ile Phe Gly Thr Pro Glu Phe Val Ala Pro Glu Ile Val Asn Tyr Glu
 180 185 190

Pro Leu Gly Leu Glu Ala Asp Met Trp Ser Ile Gly Val Ile Thr Tyr
 195 200 205

Ile Leu Leu Ser Gly Ala Ser Pro Phe Leu Gly Glu Thr Lys Gln Glu
 210 215 220

Thr Leu Thr Asn Ile Ser Ala Val Asn Tyr Asp Phe Asp Glu Glu Tyr
 225 230 235 240

Phe Ser Ser Thr Ser Glu Leu Ala Lys Asp Phe Ile Arg Arg Leu Leu
 245 250 255

Val Lys Asp Pro Lys Arg Arg Met Thr Ile Ala Gln Ser Leu Glu His
 260 265 270

Ser Trp Ile Lys Val Arg Arg Arg Glu Asp Gly Ala Arg Lys Pro Glu
 275 280 285

Arg Arg Arg Leu Arg Ala Ala Arg Leu Arg Glu Tyr Ser Leu Lys Ser
 290 295 300

His Ser Ser Met Pro Arg Asn Thr Ser Tyr Ala Ser Phe Glu Arg Phe
 305 310 315 320

Ser Arg Val Leu Glu Asp Val Ala Ala Ala Glu Gln Gly Leu Arg Glu
 325 330 335

Leu Gln Arg Gly Arg Arg Gln Cys Arg Glu Arg Val Cys Ala Leu Arg
 340 345 350

Ala Ala Ala Glu Gln Arg Glu Ala Arg Cys Arg Asp Gly Ser Ala Gly
 355 360 365

Leu Gly Arg Asp Leu Arg Arg Leu Arg Thr Glu Leu Gly Arg Thr Glu
 370 375 380

Ala Leu Arg Thr Arg Ala Gln Glu Glu Ala Arg Ala Ala Leu Leu Gly
 385 390 395 400

Ala Gly Gly Leu Lys Arg Arg Leu Cys Arg Leu Glu Asn Arg Tyr Asp
 405 410 415

Ala Leu Ala Ala Gln Val Ala Ala Glu Val Gln Phe Val Arg Asp Leu
 420 425 430

Val Arg Ala Leu Glu Gln Glu Arg Leu Gln Ala Glu Cys Gly Val Arg
 435 440 445

<210> SEQ ID NO 3
 <211> LENGTH: 2132
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (94)..(1455)

<400> SEQUENCE: 3

gttgccatta ggggactcct gaggtcctat ctccaggctg cggtgactgc actttccctg 60

gagtggaagc tgctggaagg cggaccggcc gcc atg tcc acg ttc agg cag gag 114
 Met Ser Thr Phe Arg Gln Glu
 1 5

gac gtg gag gac cat tat gag atg ggg gag gag ctg ggc agc ggc cag 162
 Asp Val Glu Asp His Tyr Glu Met Gly Glu Glu Leu Gly Ser Gly Gln
 10 15 20

ttt gcg atc gtg cgg aag tgc cgg cag aag ggc acg ggc aag gag tac 210
 Phe Ala Ile Val Arg Lys Cys Arg Gln Lys Gly Thr Gly Lys Glu Tyr
 25 30 35

-continued

gca gcc aag ttc atc aag aag cgc cgc ctg tca tcc agc cgg cgt ggg Ala Ala Lys Phe Ile Lys Lys Arg Arg Leu Ser Ser Ser Arg Arg Gly 40 45 50 55	258
gtg agc cgg gag gag atc gag cgg gag gtg aac atc ctg cgg gag atc Val Ser Arg Glu Glu Ile Glu Arg Glu Val Asn Ile Leu Arg Glu Ile 60 65 70	306
cgg cac ccc aac atc atc acc ctg cac gac atc ttc gag aac aag acg Arg His Pro Asn Ile Ile Thr Leu His Asp Ile Phe Glu Asn Lys Thr 75 80 85	354
gac gtg gtc ctc atc ctg gag ctg gtc tct ggc ggg gag ctc ttt gac Asp Val Val Leu Ile Leu Glu Leu Val Ser Gly Gly Glu Leu Phe Asp 90 95 100	402
ttc ctg gcg gag aaa gag tcg ctg acg gag gac gag gcc acc cag ttc Phe Leu Ala Glu Lys Glu Ser Leu Thr Glu Asp Glu Ala Thr Gln Phe 105 110 115	450
ctc aag cag atc ctg gac ggc gtt cac tac ctg cac tct aag cgc atc Leu Lys Gln Ile Leu Asp Gly Val His Tyr Leu His Ser Lys Arg Ile 120 125 130 135	498
gca cac ttt gac ctg aag cgg gaa aac atc atg ctg ctg gac aag aac Ala His Phe Asp Leu Lys Pro Glu Asn Ile Met Leu Leu Asp Lys Asn 140 145 150	546
gtg ccc aac cca cga atc aag ctc atc gac ttc ggc atc gcg cac aag Val Pro Asn Pro Arg Ile Lys Leu Ile Asp Phe Gly Ile Ala His Lys 155 160 165	594
atc gag gcg ggg aac gag ttc aag aac atc ttc ggc acc cgg gag ttt Ile Glu Ala Gly Asn Glu Phe Lys Asn Ile Phe Gly Thr Pro Glu Phe 170 175 180	642
gtg gcc cca gag att gtg aac tat gag ccg ctg ggc ctg gag gcg gac Val Ala Pro Glu Ile Val Asn Tyr Glu Pro Leu Gly Leu Glu Ala Asp 185 190 195	690
atg tgg agc atc ggt gtc atc acc tat atc ctc ctg agc ggt gca tcc Met Trp Ser Ile Gly Val Ile Thr Tyr Ile Leu Leu Ser Gly Ala Ser 200 205 210 215	738
ccg ttc ctg ggc gag acc aag cag gag acg ctc acc aac atc tca gcc Pro Phe Leu Gly Glu Thr Lys Gln Glu Thr Leu Thr Asn Ile Ser Ala 220 225 230	786
gtg aac tac gac ttc gac gag gag tac ttc agc aac acc agc gag ctg Val Asn Tyr Asp Phe Asp Glu Glu Tyr Phe Ser Asn Thr Ser Glu Leu 235 240 245	834
gcc aag gac ttc att cgc cgg ctg ctc gtc aaa gat ccc aag cgg aga Ala Lys Asp Phe Ile Arg Arg Leu Leu Val Lys Asp Pro Lys Arg Arg 250 255 260	882
atg acc att gcc cag agc ctg gaa cat tcc tgg att aag gcg atc cgg Met Thr Ile Ala Gln Ser Leu Glu His Ser Trp Ile Lys Ala Ile Arg 265 270 275	930
cgg cgg aac gtg cgt ggt gag gac agc ggc cgc aag ccc gag cgg cgg Arg Arg Asn Val Arg Gly Glu Asp Ser Gly Arg Lys Pro Glu Arg Arg 280 285 290 295	978
cgc ctg aag acc acg cgt ctg aag gag tac acc atc aag tcg cac tcc Arg Leu Lys Thr Thr Arg Leu Lys Glu Tyr Thr Ile Lys Ser His Ser 300 305 310	1026
agc ttg ccg ccc aac aac agc tac gcc gac ttc gag cgc ttc tcc aag Ser Leu Pro Pro Asn Asn Ser Tyr Ala Asp Phe Glu Arg Phe Ser Lys 315 320 325	1074
gtg ctg gag gag gcg gcg gcc gcc gag gag ggc ctg cgc gag ctg cag Val Leu Glu Glu Ala Ala Ala Ala Glu Glu Gly Leu Arg Glu Leu Gln 330 335 340	1122
cgc agc cgg cgg ctc tgc cac gag gac gtg gag gcg ctg gcc gcc atc Arg Ser Arg Arg Leu Cys His Glu Asp Val Glu Ala Leu Ala Ala Ile	1170

-continued

345	350	355	
tac gag gag aag gag gcc tgg tac cgc gag gag agc gac agc ctg ggc Tyr Glu Glu Lys Glu Ala Trp Tyr Arg Glu Glu Ser Asp Ser Leu Gly 360 365 370 375			1218
cag gac ctg cgg agg cta cgg cag gag ctg ctc aag acc gag gcg ctc Gln Asp Leu Arg Arg Leu Arg Gln Glu Leu Leu Lys Thr Glu Ala Leu 380 385 390			1266
aag cgg cag gcg cag gag gag gcc aag ggc gcg ctg ctg ggg acc agc Lys Arg Gln Ala Gln Glu Glu Ala Lys Gly Ala Leu Leu Gly Thr Ser 395 400 405			1314
ggc ctc aag cgc cgc ttc agc cgc ctg gag aac cgc tac gag gcg ctg Gly Leu Lys Arg Arg Phe Ser Arg Leu Glu Asn Arg Tyr Glu Ala Leu 410 415 420			1362
gcc aag caa gta gcc tcc gag atg cgc ttc gtg cag gac ctc gtg cgc Ala Lys Gln Val Ala Ser Glu Met Arg Phe Val Gln Asp Leu Val Arg 425 430 435			1410
gcc ctg gag cag gag aag ctg cag ggc gtg gag tgc ggg ctg cgc Ala Leu Glu Gln Glu Lys Leu Gln Gly Val Glu Cys Gly Leu Arg 440 445 450			1455
tagggcgcagt ggggtgggcc aggccccagg acagccggag ctcggcctgc ggtgggggag			1515
cttcctgttg acgtgcgcgc tccatcgcgc cgggtgcctg tccttgccca gcgccaccag			1575
gctggaggog gagtgggagg agctggagcc aggccgtaa gttgcaggc aggggtgggt			1635
gtgggacggg gctgcttctc tacacagcct ctacgctggc cttoaccttc acccctgcat			1695
cgctcgtgac cctgggaccc tccaggcagc gtggcctgtg gcaccgtgag ggttgggacc			1755
caccgaggog cagaggcggc ccgaatgcag ccctggttca ggccccgagg agggtttgcg			1815
ggtagtgtca cggacaattc ggcggggtgc tgcctgttgc tgccattagc ccaggaggag			1875
gtcgtgggac ggggagggtg ggatggacgg cggacaggca gtccccacgc tgctgggtgg			1935
cgccgggctt ggtgggtctc tccactgtgt gcccttctcg ccgaggccgg tccccgggt			1995
gtgggtgctc ctgctcgga ctccctccgc agccccatcg tcgcgctgt ggacgcctag			2055
gcaagagcgg ccctctgcag ccaagagaaa taaaatactg gcttccagat aaaaaaaaaa			2115
aaaaaaaaa aaaaaaa			2132
<p><210> SEQ ID NO 4 <211> LENGTH: 1429 <212> TYPE: DNA <213> ORGANISM: Mus musculus <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (10)..(1353)</p>			
<p><400> SEQUENCE: 4</p>			
ccagccgcc atg tcc aca ttc agg caa gag gat gtt gag gac cat tat gag Met Ser Thr Phe Arg Gln Glu Asp Val Glu Asp His Tyr Glu 1 5 10			51
atg gga gag gag ctt ggc agt ggc caa ttt gcc atc gtg cgc aag tgc Met Gly Glu Glu Leu Gly Ser Gly Gln Phe Ala Ile Val Arg Lys Cys 15 20 25 30			99
cag cag aag ggc acg ggc atg gag tat gca gcc aag ttc atc aag aag Gln Gln Lys Gly Thr Gly Met Glu Tyr Ala Ala Lys Phe Ile Lys Lys 35 40 45			147
cgg cgc ctg cca tcc agc cgg cgc ggt gtg agc cgg gag gag atc gaa Arg Arg Leu Pro Ser Ser Arg Arg Gly Val Ser Arg Glu Glu Ile Glu 50 55 60			195
cgc gag gtg agc atc ctg cgc gag atc cgc cac ccc aac atc ata aca Arg Glu Val Ser Ile Leu Arg Glu Ile Arg His Pro Asn Ile Ile Thr			243

-continued

65		70		75												
ctg	cat	gac	gtg	ttc	gag	aac	aag	aca	gat	gtg	gtg	ctg	atc	ctg	gag	291
Leu	His	Asp	Val	Phe	Glu	Asn	Lys	Thr	Asp	Val	Val	Leu	Ile	Leu	Glu	
	80					85					90					
ctg	gtg	tcc	ggt	ggc	gag	ctt	ttc	gac	ttc	ctg	gcc	gag	aag	gag	tca	339
Leu	Val	Ser	Gly	Gly	Glu	Leu	Phe	Asp	Phe	Leu	Ala	Glu	Lys	Glu	Ser	
	95			100						105					110	
ttg	acg	gag	gat	gag	gcc	acg	cag	ttc	ctc	aaa	caa	atc	cta	gac	ggt	387
Leu	Thr	Glu	Asp	Gly	Glu	Ala	Thr	Gln	Phe	Leu	Lys	Gln	Ile	Leu	Asp	Gly
				115					120					125		
gtc	cac	tac	ctg	cac	tcc	aag	cgc	atc	gca	cac	ttt	gac	ctg	aag	ccc	435
Val	His	Tyr	Leu	His	Ser	Lys	Arg	Ile	Ala	His	Phe	Asp	Leu	Lys	Pro	
			130					135						140		
gag	aac	atc	atg	ttg	ctg	gac	aag	cac	gca	gcc	agc	ccc	cgc	att	aag	483
Glu	Asn	Ile	Met	Leu	Leu	Asp	Lys	His	Ala	Ala	Ser	Pro	Arg	Ile	Lys	
	145					150						155				
ctc	atc	gac	ttt	ggc	atc	gcg	cac	agg	atc	gag	gct	ggc	agc	gag	ttc	531
Leu	Ile	Asp	Phe	Gly	Ile	Ala	His	Arg	Ile	Glu	Ala	Gly	Ser	Glu	Phe	
	160					165					170					
aag	aac	atc	ttt	ggc	aca	ccc	gag	ttt	gtc	gcc	ccc	gag	atc	gtg	aac	579
Lys	Asn	Ile	Phe	Gly	Thr	Pro	Glu	Phe	Val	Ala	Pro	Glu	Ile	Val	Asn	
	175				180					185					190	
tat	gag	cca	ctt	ggc	ttg	gag	gct	gac	atg	tgg	agc	att	ggc	gtc	atc	627
Tyr	Glu	Pro	Leu	Gly	Leu	Glu	Ala	Asp	Met	Trp	Ser	Ile	Gly	Val	Ile	
				195					200					205		
acc	tac	atc	ctc	ctg	agc	gga	gcg	tcc	cca	ttc	ctg	ggc	gag	acc	aag	675
Thr	Tyr	Ile	Leu	Leu	Ser	Gly	Ala	Ser	Pro	Phe	Leu	Gly	Glu	Thr	Lys	
			210					215					220			
cag	gag	acg	ctg	acg	aac	atc	tca	gca	gtg	aac	tat	gac	ttt	gat	gag	723
Gln	Glu	Thr	Leu	Thr	Asn	Ile	Ser	Ala	Val	Asn	Tyr	Asp	Phe	Asp	Glu	
		225				230						235				
gaa	tac	ttc	agc	agc	acc	agc	gag	ctg	gcc	aag	gac	ttc	atc	cgc	agg	771
Glu	Tyr	Phe	Ser	Ser	Thr	Ser	Glu	Leu	Ala	Lys	Asp	Phe	Ile	Arg	Arg	
	240					245					250					
ctg	ctg	gtc	aaa	gac	ccc	aag	agg	agg	atg	acc	atc	gca	cag	agc	ctg	819
Leu	Leu	Val	Lys	Asp	Pro	Lys	Arg	Arg	Met	Thr	Ile	Ala	Gln	Ser	Leu	
	255				260				265						270	
gag	cat	tcc	tgg	atc	aag	gtg	cgc	agg	cgc	gag	gac	ggc	gcc	cgg	aag	867
Glu	His	Ser	Trp	Ile	Lys	Val	Arg	Arg	Arg	Glu	Asp	Gly	Ala	Arg	Lys	
				275					280					285		
cca	gag	cga	cgg	cgg	ctg	cgc	gcc	gcg	cgc	ctg	cgc	gag	tac	agc	ctc	915
Pro	Glu	Arg	Arg	Arg	Leu	Arg	Ala	Ala	Arg	Leu	Arg	Glu	Tyr	Ser	Leu	
			290					295					300			
aag	tcc	cac	tcg	agc	atg	ccg	cgc	aac	acg	agc	tac	gcc	agc	ttc	gag	963
Lys	Ser	His	Ser	Ser	Met	Pro	Arg	Asn	Thr	Ser	Tyr	Ala	Ser	Phe	Glu	
		305						310				315				
cgc	ttc	tca	cgc	gtg	ctg	gag	gac	gtg	gcg	gcg	gca	gag	cag	ggg	ctg	1011
Arg	Phe	Ser	Arg	Val	Leu	Glu	Asp	Val	Ala	Ala	Ala	Glu	Gln	Gly	Leu	
		320				325						330				
cgc	gag	ctg	cag	cga	ggc	agg	cgc	cag	tgc	cgg	gag	cgc	gtg	tgt	gcg	1059
Arg	Glu	Leu	Gln	Arg	Gly	Arg	Arg	Gln	Cys	Arg	Glu	Arg	Val	Cys	Ala	
					340					345					350	
ctg	cgc	gcg	gcc	gcc	gag	cag	cgg	gag	gcg	cgc	tgc	cgc	gac	ggg	agc	1107
Leu	Arg	Ala	Ala	Ala	Glu	Gln	Arg	Glu	Ala	Arg	Cys	Arg	Asp	Gly	Ser	
				355					360					365		
gca	ggg	cta	ggg	cgc	gac	ctg	cga	cgc	ctg	cgc	acg	gag	ctg	ggg	cgc	1155
Ala	Gly	Leu	Gly	Arg	Asp	Leu	Arg	Arg	Leu	Arg	Thr	Glu	Leu	Gly	Arg	
			370					375					380			
acc	gag	gct	ctg	cgc	acg	cgc	gcg	cag	gag	gag	gcg	cgg	gcg	gcg	ctg	1203

25

What is claimed is:

1. An isolated DNA coding for a protein selected from the group consisting of:
 - (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 1; and
 - (b) a protein comprising an amino acid sequence having the amino acid sequence as shown in SEQ ID NO: 1 in which the first amino acid is deleted.
2. A DNA coding for a protein selected from the group consisting of:
 - (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2; and
 - (b) a protein comprising an amino acid sequence having the amino acid sequence as shown in SEQ ID NO: 2 in which the 42nd amino acid residue is changed to alanine; and
 - (c) a protein comprising an amino acid sequence having the amino acid sequence as shown in SEQ ID NO: 2 in

26

which the 422nd, 429th and 436th amino acid residues are changed to alanines.

3. The DNA of claim 1, comprising the nucleic acid sequence of SEQ ID NO: 3.
4. The DNA of claim 2, comprising the nucleic acid sequence of SEQ ID NO: 4.
5. A recombinant vector comprising a DNA of claim 1.
6. A transformant transformed with a recombinant vector of claim 5.
7. A recombinant vector comprising a DNA of claim 2.
8. A recombinant vector comprising a DNA of claim 3.
9. A recombinant vector comprising a DNA of claim 4.
10. A process for producing a serine/threonine kinase, comprising cultivating a transformant of claim 6 in a culture medium and collecting the serine/threonine kinase from the resulting culture.

* * * * *